Oculus Innovative Sciences Upgraded at Zacks (OCLS)
Oculus Innovative Sciences (NASDAQ:OCLS) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued to investors on Tuesday. The firm currently has a $2.70 target price on the stock. Zacks‘s price target would indicate a potential upside of 1.89% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet upgraded shares of Oculus Innovative Sciences from a “sell” rating to a “hold” rating in a research note on Monday, June 16th. Analysts at Sidoti downgraded shares of Oculus Innovative Sciences from a “buy” rating to a “neutral” rating in a research note on Friday, June 13th.
Oculus Innovative Sciences (NASDAQ:OCLS) traded down 0.38% during mid-day trading on Tuesday, hitting $2.64. 35,679 shares of the company’s stock traded hands. Oculus Innovative Sciences has a 52-week low of $2.20 and a 52-week high of $7.21. The stock has a 50-day moving average of $2.72 and a 200-day moving average of $3.32. The company has a market cap of $22.4 million and a price-to-earnings ratio of 3.62.
Oculus Innovative Sciences (NASDAQ:OCLS) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.16. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Analysts expect that Oculus Innovative Sciences will post $-0.41 EPS for the current fiscal year.
Oculus Innovative Sciences, Inc is a global healthcare company that designs, produces, and markets prescription and non-prescription products in over 20 countries.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.